Share Price and Basic Stock Data
Last Updated: December 24, 2025, 4:20 pm
| PEG Ratio | 3.78 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Alkem Laboratories Ltd, a prominent player in the Indian pharmaceutical sector, reported impressive revenue growth, with total sales rising from ₹10,634 Cr in FY 2022 to ₹11,599 Cr in FY 2023, and further increasing to ₹12,668 Cr in FY 2024. This upward trend continued, culminating in a TTM revenue of ₹13,890 Cr. The company’s quarterly sales have shown notable fluctuations, with a peak of ₹3,440 Cr in Sep 2023, which reflects robust demand for its pharmaceutical products. The operating profit margin (OPM) has shown resilience, standing at 19% for FY 2025 and demonstrating an improvement from 14% in FY 2023. The company has effectively navigated market dynamics, as evidenced by a consistent increase in quarterly sales, with Jun 2025 sales reported at ₹3,371 Cr. This growth trajectory positions Alkem favorably within the competitive pharmaceutical landscape, indicating strong operational capabilities and market demand for its offerings.
Profitability and Efficiency Metrics
Alkem Laboratories has demonstrated commendable profitability metrics, with a reported net profit of ₹2,215 Cr for FY 2025, reflecting a significant increase from ₹1,007 Cr in FY 2023. The company’s return on equity (ROE) stood at 19.4%, indicating effective management of shareholder funds. Profit margins have also improved, with the net profit margin reaching 17.09% in FY 2025, compared to 8.67% in FY 2023. Efficiency ratios are noteworthy, with a cash conversion cycle (CCC) of 152 days, underscoring the company’s ability to convert investments into cash flows efficiently. The interest coverage ratio (ICR) is robust at 24.70x, which indicates that the company can comfortably meet its interest obligations, reflecting strong operational cash flows. These profitability and efficiency metrics not only highlight Alkem’s operational excellence but also its ability to generate shareholder value consistently.
Balance Sheet Strength and Financial Ratios
Alkem Laboratories’ balance sheet exhibits resilience, with total assets reported at ₹17,691 Cr in FY 2025, up from ₹13,757 Cr in FY 2023. The company maintains a sound capital structure, with total borrowings amounting to ₹1,381 Cr, translating to a conservative total debt-to-equity ratio of 0.08x. This financial leverage indicates prudent management of debt, enhancing the company’s financial stability. Additionally, the reserves have grown significantly, standing at ₹13,322 Cr, which bolsters the company’s ability to reinvest in growth opportunities. The price-to-book value (P/BV) ratio of 4.87x suggests that the stock may be trading at a premium compared to its book value, reflecting investor confidence. Furthermore, the current ratio is robust at 2.76x, indicating strong liquidity to cover short-term obligations. Overall, the balance sheet reflects a strong financial position, essential for supporting future growth initiatives.
Shareholding Pattern and Investor Confidence
Alkem’s shareholding pattern illustrates a stable ownership structure, with promoters holding 51.20% of the shares, indicating strong management control. The presence of foreign institutional investors (FIIs) at 9.47% and domestic institutional investors (DIIs) at 21.93% reflects a healthy interest from institutional players, suggesting confidence in the company’s long-term prospects. The public shareholding stands at 17.39%, with a total of 67,196 shareholders, indicating a diverse shareholder base. Over recent quarters, there has been a slight decline in promoter holding from 57.16% in Dec 2022 to the current 51.20%, which could raise concerns about management’s control. Conversely, the increase in DII holdings from 16.44% in Dec 2022 to 21.93% in Sep 2025 demonstrates growing institutional confidence. This balanced shareholding structure supports stability and potential growth, reflecting positively on investor sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Alkem Laboratories is well-positioned for continued growth, driven by its strong revenue trajectory and efficient operational metrics. However, risks remain, including potential regulatory challenges in the pharmaceutical sector and increasing competition, which could impact profit margins. Additionally, fluctuations in raw material prices may affect cost structures. On the upside, the company’s focus on research and development can lead to the introduction of innovative products, enhancing market share. Should Alkem successfully navigate regulatory landscapes and maintain its operational efficiency, it could sustain its growth momentum. In a scenario where market conditions remain favorable, the company could expand its product portfolio and geographic reach, further solidifying its standing in the pharmaceutical industry. Conversely, adverse regulatory changes or intensified competition could hinder growth, underscoring the importance of strategic adaptability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 132 Cr. | 105 | 231/84.3 | 29.2 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,793 Cr. | 440 | 479/192 | 99.2 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 49.7 Cr. | 34.0 | 35.0/17.0 | 118 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,170.56 Cr | 1,150.06 | 53.01 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,576 | 3,079 | 3,041 | 2,903 | 2,968 | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 |
| Expenses | 2,373 | 2,625 | 2,442 | 2,549 | 2,579 | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 |
| Operating Profit | 203 | 454 | 599 | 353 | 389 | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 |
| OPM % | 8% | 15% | 20% | 12% | 13% | 22% | 21% | 14% | 20% | 22% | 23% | 12% | 22% |
| Other Income | 51 | 51 | 45 | -34 | 66 | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 |
| Interest | 26 | 25 | 27 | 29 | 30 | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 |
| Depreciation | 76 | 77 | 78 | 78 | 72 | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 |
| Profit before tax | 152 | 402 | 539 | 212 | 353 | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 |
| Tax % | 13% | 14% | 15% | 68% | 18% | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% |
| Net Profit | 131 | 348 | 460 | 68 | 288 | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 |
| EPS in Rs | 10.68 | 27.67 | 38.03 | 5.94 | 23.98 | 51.90 | 49.76 | 24.55 | 45.60 | 57.60 | 52.34 | 25.58 | 55.56 |
Last Updated: August 20, 2025, 2:00 pm
Below is a detailed analysis of the quarterly data for Alkem Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,371.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,144.00 Cr. (Mar 2025) to 3,371.00 Cr., marking an increase of 227.00 Cr..
- For Expenses, as of Jun 2025, the value is 2,632.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2,752.00 Cr. (Mar 2025) to 2,632.00 Cr., marking a decrease of 120.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 739.00 Cr.. The value appears strong and on an upward trend. It has increased from 391.00 Cr. (Mar 2025) to 739.00 Cr., marking an increase of 348.00 Cr..
- For OPM %, as of Jun 2025, the value is 22.00%. The value appears strong and on an upward trend. It has increased from 12.00% (Mar 2025) to 22.00%, marking an increase of 10.00%.
- For Other Income, as of Jun 2025, the value is 149.00 Cr.. The value appears strong and on an upward trend. It has increased from 146.00 Cr. (Mar 2025) to 149.00 Cr., marking an increase of 3.00 Cr..
- For Interest, as of Jun 2025, the value is 30.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28.00 Cr. (Mar 2025) to 30.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 88.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 112.00 Cr. (Mar 2025) to 88.00 Cr., marking a decrease of 24.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 771.00 Cr.. The value appears strong and on an upward trend. It has increased from 396.00 Cr. (Mar 2025) to 771.00 Cr., marking an increase of 375.00 Cr..
- For Tax %, as of Jun 2025, the value is 13.00%. The value appears to be improving (decreasing) as expected. It has decreased from 18.00% (Mar 2025) to 13.00%, marking a decrease of 5.00%.
- For Net Profit, as of Jun 2025, the value is 668.00 Cr.. The value appears strong and on an upward trend. It has increased from 322.00 Cr. (Mar 2025) to 668.00 Cr., marking an increase of 346.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 55.56. The value appears strong and on an upward trend. It has increased from 25.58 (Mar 2025) to 55.56, marking an increase of 29.98.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,113 | 3,674 | 4,905 | 5,688 | 6,401 | 7,357 | 8,344 | 8,865 | 10,634 | 11,599 | 12,668 | 12,965 | 13,890 |
| Expenses | 2,700 | 3,248 | 4,038 | 4,687 | 5,392 | 6,237 | 6,868 | 6,920 | 8,580 | 9,977 | 10,419 | 10,452 | 11,080 |
| Operating Profit | 413 | 427 | 866 | 1,001 | 1,009 | 1,120 | 1,476 | 1,945 | 2,054 | 1,622 | 2,249 | 2,512 | 2,810 |
| OPM % | 13% | 12% | 18% | 18% | 16% | 15% | 18% | 22% | 19% | 14% | 18% | 19% | 20% |
| Other Income | 162 | 176 | 227 | 110 | 115 | 82 | 102 | 230 | 146 | 101 | 186 | 494 | 492 |
| Interest | 93 | 81 | 71 | 45 | 55 | 55 | 65 | 59 | 52 | 107 | 112 | 122 | 129 |
| Depreciation | 52 | 71 | 93 | 101 | 143 | 193 | 253 | 275 | 304 | 310 | 299 | 357 | 379 |
| Profit before tax | 430 | 451 | 928 | 965 | 926 | 955 | 1,260 | 1,842 | 1,844 | 1,305 | 2,023 | 2,527 | 2,794 |
| Tax % | -1% | 13% | 19% | 6% | 31% | 19% | 9% | 12% | 9% | 23% | 10% | 12% | |
| Net Profit | 435 | 392 | 752 | 905 | 638 | 774 | 1,149 | 1,618 | 1,680 | 1,007 | 1,811 | 2,215 | 2,410 |
| EPS in Rs | 364.10 | 32.75 | 62.02 | 74.61 | 52.77 | 63.61 | 94.26 | 132.57 | 137.63 | 82.31 | 150.19 | 181.11 | 197.47 |
| Dividend Payout % | 5% | 12% | 20% | 20% | 25% | 25% | 27% | 23% | 25% | 61% | 27% | 25% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -9.89% | 91.84% | 20.35% | -29.50% | 21.32% | 48.45% | 40.82% | 3.83% | -40.06% | 79.84% | 22.31% |
| Change in YoY Net Profit Growth (%) | 0.00% | 101.72% | -71.49% | -49.85% | 50.82% | 27.13% | -7.63% | -36.99% | -43.89% | 119.90% | -57.53% |
Alkem Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 9% |
| 3 Years: | 7% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 14% |
| 3 Years: | 9% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 20% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 19% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 4, 2025, 10:45 pm
Balance Sheet
Last Updated: December 4, 2025, 12:56 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 2,567 | 2,975 | 3,668 | 4,444 | 4,840 | 5,415 | 6,137 | 7,353 | 8,614 | 9,021 | 10,288 | 11,961 | 13,322 |
| Borrowings | 1,128 | 1,306 | 658 | 659 | 998 | 944 | 1,616 | 1,707 | 2,668 | 1,397 | 1,418 | 1,381 | 2,356 |
| Other Liabilities | 604 | 986 | 1,184 | 1,440 | 1,803 | 1,824 | 2,169 | 2,435 | 2,763 | 3,315 | 3,844 | 4,325 | 4,586 |
| Total Liabilities | 4,311 | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,287 |
| Fixed Assets | 1,170 | 1,374 | 1,450 | 1,797 | 2,284 | 2,530 | 2,908 | 2,793 | 2,902 | 2,683 | 2,873 | 2,852 | 3,319 |
| CWIP | 0 | 111 | 172 | 299 | 381 | 493 | 363 | 393 | 339 | 323 | 159 | 548 | 653 |
| Investments | 588 | 481 | 509 | 553 | 444 | 324 | 261 | 333 | 371 | 622 | 484 | 1,846 | 2,533 |
| Other Assets | 2,553 | 3,325 | 3,403 | 3,918 | 4,555 | 4,861 | 6,413 | 8,000 | 10,457 | 10,129 | 12,060 | 12,445 | 13,783 |
| Total Assets | 4,311 | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,287 |
Below is a detailed analysis of the balance sheet data for Alkem Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Reserves, as of Sep 2025, the value is 13,322.00 Cr.. The value appears strong and on an upward trend. It has increased from 11,961.00 Cr. (Mar 2025) to 13,322.00 Cr., marking an increase of 1,361.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,356.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,381.00 Cr. (Mar 2025) to 2,356.00 Cr., marking an increase of 975.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4,586.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,325.00 Cr. (Mar 2025) to 4,586.00 Cr., marking an increase of 261.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 20,287.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17,691.00 Cr. (Mar 2025) to 20,287.00 Cr., marking an increase of 2,596.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3,319.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,852.00 Cr. (Mar 2025) to 3,319.00 Cr., marking an increase of 467.00 Cr..
- For CWIP, as of Sep 2025, the value is 653.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Mar 2025) to 653.00 Cr., marking an increase of 105.00 Cr..
- For Investments, as of Sep 2025, the value is 2,533.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,846.00 Cr. (Mar 2025) to 2,533.00 Cr., marking an increase of 687.00 Cr..
- For Other Assets, as of Sep 2025, the value is 13,783.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,445.00 Cr. (Mar 2025) to 13,783.00 Cr., marking an increase of 1,338.00 Cr..
- For Total Assets, as of Sep 2025, the value is 20,287.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,691.00 Cr. (Mar 2025) to 20,287.00 Cr., marking an increase of 2,596.00 Cr..
Notably, the Reserves (13,322.00 Cr.) exceed the Borrowings (2,356.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 412.00 | 426.00 | 208.00 | -658.00 | -997.00 | -943.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43 | 52 | 42 | 46 | 62 | 62 | 72 | 66 | 65 | 67 | 65 | 69 |
| Inventory Days | 163 | 169 | 169 | 198 | 221 | 186 | 198 | 241 | 262 | 194 | 197 | 224 |
| Days Payable | 81 | 101 | 108 | 122 | 147 | 119 | 104 | 112 | 102 | 87 | 129 | 141 |
| Cash Conversion Cycle | 126 | 121 | 103 | 122 | 135 | 129 | 167 | 196 | 225 | 174 | 132 | 152 |
| Working Capital Days | -26 | -52 | 13 | 34 | 40 | 55 | 44 | 47 | 31 | 66 | 135 | 124 |
| ROCE % | 14% | 12% | 23% | 21% | 17% | 16% | 18% | 22% | 18% | 14% | 20% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid Cap Fund | 1,802,978 | 1.11 | 1024.99 | 1,545,839 | 2025-12-14 00:38:48 | 16.63% |
| SBI Large & Midcap Fund | 1,476,712 | 2.27 | 839.51 | N/A | N/A | N/A |
| ICICI Prudential Multi Asset Fund | 1,450,072 | 1.1 | 824.37 | 388,526 | 2025-12-07 23:08:50 | 273.22% |
| Nippon India Growth Mid Cap Fund | 1,163,397 | 1.57 | 661.39 | N/A | N/A | N/A |
| ICICI Prudential Large & Mid Cap Fund | 1,121,797 | 2.37 | 637.74 | 1,176,641 | 2025-12-14 02:28:49 | -4.66% |
| SBI Contra Fund | 1,004,007 | 1.15 | 570.78 | 452,400 | 2025-12-07 15:45:16 | 121.93% |
| DSP Mid Cap Fund | 748,010 | 2.14 | 425.24 | 1,566,421 | 2025-12-07 16:59:56 | -52.25% |
| SBI Midcap Fund | 685,892 | 1.67 | 389.93 | N/A | N/A | N/A |
| ICICI Prudential ELSS Tax Saver Fund | 464,445 | 1.77 | 264.04 | 499,784 | 2025-12-14 21:24:23 | -7.07% |
| Axis Midcap Fund | 461,670 | 0.82 | 262.46 | 813,160 | 2025-12-06 16:16:03 | -43.23% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 181.11 | 150.19 | 82.31 | 137.63 | 132.57 |
| Diluted EPS (Rs.) | 181.11 | 150.19 | 82.31 | 137.63 | 132.57 |
| Cash EPS (Rs.) | 215.24 | 176.56 | 110.18 | 165.98 | 158.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1002.50 | 896.23 | 789.21 | 740.05 | 632.20 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1002.50 | 896.23 | 789.21 | 740.05 | 632.20 |
| Revenue From Operations / Share (Rs.) | 1084.44 | 1059.61 | 970.24 | 889.52 | 741.53 |
| PBDIT / Share (Rs.) | 251.43 | 213.83 | 152.70 | 185.33 | 181.98 |
| PBIT / Share (Rs.) | 221.56 | 188.79 | 126.73 | 159.90 | 159.01 |
| PBT / Share (Rs.) | 211.38 | 169.23 | 109.14 | 154.27 | 154.09 |
| Net Profit / Share (Rs.) | 185.36 | 151.52 | 84.22 | 140.55 | 135.32 |
| NP After MI And SOA / Share (Rs.) | 181.14 | 150.21 | 82.32 | 137.65 | 132.58 |
| PBDIT Margin (%) | 23.18 | 20.18 | 15.73 | 20.83 | 24.54 |
| PBIT Margin (%) | 20.43 | 17.81 | 13.06 | 17.97 | 21.44 |
| PBT Margin (%) | 19.49 | 15.97 | 11.24 | 17.34 | 20.77 |
| Net Profit Margin (%) | 17.09 | 14.29 | 8.67 | 15.80 | 18.24 |
| NP After MI And SOA Margin (%) | 16.70 | 14.17 | 8.48 | 15.47 | 17.87 |
| Return on Networth / Equity (%) | 18.06 | 17.41 | 10.88 | 19.05 | 21.48 |
| Return on Capital Employeed (%) | 19.29 | 19.49 | 15.07 | 20.63 | 24.01 |
| Return On Assets (%) | 12.24 | 11.52 | 7.15 | 11.69 | 13.75 |
| Long Term Debt / Equity (X) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.08 | 0.11 | 0.14 | 0.29 | 0.22 |
| Asset Turnover Ratio (%) | 0.77 | 0.86 | 0.83 | 0.71 | 0.69 |
| Current Ratio (X) | 2.76 | 2.61 | 2.35 | 1.76 | 1.92 |
| Quick Ratio (X) | 2.02 | 1.94 | 1.65 | 1.13 | 1.28 |
| Inventory Turnover Ratio (X) | 4.64 | 1.25 | 1.09 | 1.33 | 1.23 |
| Dividend Payout Ratio (NP) (%) | 23.18 | 29.96 | 53.45 | 0.00 | 21.12 |
| Dividend Payout Ratio (CP) (%) | 19.90 | 25.68 | 40.63 | 0.00 | 18.00 |
| Earning Retention Ratio (%) | 76.82 | 70.04 | 46.55 | 0.00 | 78.88 |
| Cash Earning Retention Ratio (%) | 80.10 | 74.32 | 59.37 | 0.00 | 82.00 |
| Interest Coverage Ratio (X) | 24.70 | 22.74 | 17.00 | 42.31 | 36.92 |
| Interest Coverage Ratio (Post Tax) (X) | 19.21 | 18.20 | 11.34 | 33.37 | 28.46 |
| Enterprise Value (Cr.) | 58288.87 | 59097.05 | 39701.27 | 43453.40 | 33002.69 |
| EV / Net Operating Revenue (X) | 4.50 | 4.67 | 3.42 | 4.09 | 3.72 |
| EV / EBITDA (X) | 19.39 | 23.12 | 21.75 | 19.61 | 15.17 |
| MarketCap / Net Operating Revenue (X) | 4.50 | 4.66 | 3.50 | 4.07 | 3.74 |
| Retention Ratios (%) | 76.81 | 70.03 | 46.54 | 0.00 | 78.87 |
| Price / BV (X) | 4.87 | 5.73 | 4.49 | 5.01 | 4.49 |
| Price / Net Operating Revenue (X) | 4.50 | 4.66 | 3.50 | 4.07 | 3.74 |
| EarningsYield | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 |
After reviewing the key financial ratios for Alkem Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 181.11. This value is within the healthy range. It has increased from 150.19 (Mar 24) to 181.11, marking an increase of 30.92.
- For Diluted EPS (Rs.), as of Mar 25, the value is 181.11. This value is within the healthy range. It has increased from 150.19 (Mar 24) to 181.11, marking an increase of 30.92.
- For Cash EPS (Rs.), as of Mar 25, the value is 215.24. This value is within the healthy range. It has increased from 176.56 (Mar 24) to 215.24, marking an increase of 38.68.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,002.50. It has increased from 896.23 (Mar 24) to 1,002.50, marking an increase of 106.27.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,002.50. It has increased from 896.23 (Mar 24) to 1,002.50, marking an increase of 106.27.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,084.44. It has increased from 1,059.61 (Mar 24) to 1,084.44, marking an increase of 24.83.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 251.43. This value is within the healthy range. It has increased from 213.83 (Mar 24) to 251.43, marking an increase of 37.60.
- For PBIT / Share (Rs.), as of Mar 25, the value is 221.56. This value is within the healthy range. It has increased from 188.79 (Mar 24) to 221.56, marking an increase of 32.77.
- For PBT / Share (Rs.), as of Mar 25, the value is 211.38. This value is within the healthy range. It has increased from 169.23 (Mar 24) to 211.38, marking an increase of 42.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 185.36. This value is within the healthy range. It has increased from 151.52 (Mar 24) to 185.36, marking an increase of 33.84.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 181.14. This value is within the healthy range. It has increased from 150.21 (Mar 24) to 181.14, marking an increase of 30.93.
- For PBDIT Margin (%), as of Mar 25, the value is 23.18. This value is within the healthy range. It has increased from 20.18 (Mar 24) to 23.18, marking an increase of 3.00.
- For PBIT Margin (%), as of Mar 25, the value is 20.43. This value exceeds the healthy maximum of 20. It has increased from 17.81 (Mar 24) to 20.43, marking an increase of 2.62.
- For PBT Margin (%), as of Mar 25, the value is 19.49. This value is within the healthy range. It has increased from 15.97 (Mar 24) to 19.49, marking an increase of 3.52.
- For Net Profit Margin (%), as of Mar 25, the value is 17.09. This value exceeds the healthy maximum of 10. It has increased from 14.29 (Mar 24) to 17.09, marking an increase of 2.80.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 16.70. This value is within the healthy range. It has increased from 14.17 (Mar 24) to 16.70, marking an increase of 2.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 18.06. This value is within the healthy range. It has increased from 17.41 (Mar 24) to 18.06, marking an increase of 0.65.
- For Return on Capital Employeed (%), as of Mar 25, the value is 19.29. This value is within the healthy range. It has decreased from 19.49 (Mar 24) to 19.29, marking a decrease of 0.20.
- For Return On Assets (%), as of Mar 25, the value is 12.24. This value is within the healthy range. It has increased from 11.52 (Mar 24) to 12.24, marking an increase of 0.72.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.02, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.08. This value is within the healthy range. It has decreased from 0.11 (Mar 24) to 0.08, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.77. It has decreased from 0.86 (Mar 24) to 0.77, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 2.76. This value is within the healthy range. It has increased from 2.61 (Mar 24) to 2.76, marking an increase of 0.15.
- For Quick Ratio (X), as of Mar 25, the value is 2.02. This value exceeds the healthy maximum of 2. It has increased from 1.94 (Mar 24) to 2.02, marking an increase of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.64. This value is within the healthy range. It has increased from 1.25 (Mar 24) to 4.64, marking an increase of 3.39.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.18. This value is within the healthy range. It has decreased from 29.96 (Mar 24) to 23.18, marking a decrease of 6.78.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 19.90. This value is below the healthy minimum of 20. It has decreased from 25.68 (Mar 24) to 19.90, marking a decrease of 5.78.
- For Earning Retention Ratio (%), as of Mar 25, the value is 76.82. This value exceeds the healthy maximum of 70. It has increased from 70.04 (Mar 24) to 76.82, marking an increase of 6.78.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 80.10. This value exceeds the healthy maximum of 70. It has increased from 74.32 (Mar 24) to 80.10, marking an increase of 5.78.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 24.70. This value is within the healthy range. It has increased from 22.74 (Mar 24) to 24.70, marking an increase of 1.96.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 19.21. This value is within the healthy range. It has increased from 18.20 (Mar 24) to 19.21, marking an increase of 1.01.
- For Enterprise Value (Cr.), as of Mar 25, the value is 58,288.87. It has decreased from 59,097.05 (Mar 24) to 58,288.87, marking a decrease of 808.18.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. It has decreased from 4.67 (Mar 24) to 4.50, marking a decrease of 0.17.
- For EV / EBITDA (X), as of Mar 25, the value is 19.39. This value exceeds the healthy maximum of 15. It has decreased from 23.12 (Mar 24) to 19.39, marking a decrease of 3.73.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. It has decreased from 4.66 (Mar 24) to 4.50, marking a decrease of 0.16.
- For Retention Ratios (%), as of Mar 25, the value is 76.81. This value exceeds the healthy maximum of 70. It has increased from 70.03 (Mar 24) to 76.81, marking an increase of 6.78.
- For Price / BV (X), as of Mar 25, the value is 4.87. This value exceeds the healthy maximum of 3. It has decreased from 5.73 (Mar 24) to 4.87, marking a decrease of 0.86.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.50. This value exceeds the healthy maximum of 3. It has decreased from 4.66 (Mar 24) to 4.50, marking a decrease of 0.16.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alkem Laboratories Ltd:
- Net Profit Margin: 17.09%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 19.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 18.06% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 19.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.02
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.3 (Industry average Stock P/E: 53.01)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.08
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.09%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Alkem House, Senapati Bapat Marg, Mumbai Maharashtra 400013 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Basudeo N Singh | Executive Chairman |
| Mr. Sandeep Singh | Managing Director |
| Mrs. Madhurima Singh | Executive Director |
| Mr. Srinivas Singh | Executive Director |
| Mr. Mritunjay Kumar Singh | Executive Director |
| Mr. Sarvesh Singh | Executive Director |
| Mr. Sujjain Talwar | Independent Director |
| Mr. Narendra Kumar Aneja | Independent Director |
| Mr. Rajeev Kher | Independent Director |
| Mr. Ranjal Laxmana Shenoy | Independent Director |
| Ms. Neela Bhattacherjee | Independent Director |
| Mr. Diwakar Gupta | Independent Director |
FAQ
What is the intrinsic value of Alkem Laboratories Ltd?
Alkem Laboratories Ltd's intrinsic value (as of 24 December 2025) is 4940.86 which is 11.25% lower the current market price of 5,567.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 66,559 Cr. market cap, FY2025-2026 high/low of 5,868/4,492, reserves of ₹13,322 Cr, and liabilities of 20,287 Cr.
What is the Market Cap of Alkem Laboratories Ltd?
The Market Cap of Alkem Laboratories Ltd is 66,559 Cr..
What is the current Stock Price of Alkem Laboratories Ltd as on 24 December 2025?
The current stock price of Alkem Laboratories Ltd as on 24 December 2025 is 5,567.
What is the High / Low of Alkem Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alkem Laboratories Ltd stocks is 5,868/4,492.
What is the Stock P/E of Alkem Laboratories Ltd?
The Stock P/E of Alkem Laboratories Ltd is 28.3.
What is the Book Value of Alkem Laboratories Ltd?
The Book Value of Alkem Laboratories Ltd is 1,116.
What is the Dividend Yield of Alkem Laboratories Ltd?
The Dividend Yield of Alkem Laboratories Ltd is 0.80 %.
What is the ROCE of Alkem Laboratories Ltd?
The ROCE of Alkem Laboratories Ltd is 20.4 %.
What is the ROE of Alkem Laboratories Ltd?
The ROE of Alkem Laboratories Ltd is 19.4 %.
What is the Face Value of Alkem Laboratories Ltd?
The Face Value of Alkem Laboratories Ltd is 2.00.